A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
Kestrel Therapeutics, Inc.
Kestrel Therapeutics, Inc.
Ohio State University Comprehensive Cancer Center
Memorial Sloan Kettering Cancer Center
Shanghai Junshi Bioscience Co., Ltd.
NRG Oncology
Assistance Publique - Hôpitaux de Paris
Memorial Sloan Kettering Cancer Center
Institut Paoli-Calmettes
Mayo Clinic
M.D. Anderson Cancer Center
Stanford University
Fred Hutchinson Cancer Center
Mayo Clinic
Mayo Clinic
Tomsk National Research Medical Center of the Russian Academy of Sciences
University Hospital Heidelberg
University of Mississippi Medical Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Essen Biotech
Essen Biotech
OHSU Knight Cancer Institute
University of Oklahoma
Centre Paul Strauss
Royal Marsden NHS Foundation Trust
Kidney Cancer Research Bureau
Mayo Clinic
The First Affiliated Hospital of Guangzhou Medical University
Massachusetts General Hospital
Abramson Cancer Center at Penn Medicine
Hospices Civils de Lyon
City of Hope Medical Center
University of California, San Diego
University of Texas Southwestern Medical Center
Hoosier Cancer Research Network
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Institut Bergonié
Institut Bergonié
Hadassah Medical Organization
Centre Georges Francois Leclerc
MedSIR
Hopitaux Prives de Metz, Groupe UNEOS
NYU Langone Health
Lady Davis Institute
NuCana plc
UNC Lineberger Comprehensive Cancer Center
University of Washington
Bank of Cyprus Oncology Centre
NRG Oncology